公开(公告)号：US20240139158A1

公开(公告)日：2024-05-02

申请号：US18542018

申请日：2023-12-15

Applicant: Proteostasis Therapeutics, Inc.

Inventor： John Miller ,  Cecilia M. Bastos ,  Benito Munoz

IPC: A61K31/422 ,  A61K9/00 ,  A61K31/341 ,  A61K31/404 ,  A61K31/4192 ,  A61K31/4245 ,  A61K31/433 ,  A61K31/443 ,  A61K31/454 ,  A61K31/47 ,  A61K31/5377 ,  A61K31/7036 ,  A61K45/06 ,  A61P11/06 ,  A61P11/08

CPC classification number: A61K31/422 ,  A61K9/0053 ,  A61K9/0073 ,  A61K31/341 ,  A61K31/404 ,  A61K31/4192 ,  A61K31/4245 ,  A61K31/433 ,  A61K31/443 ,  A61K31/454 ,  A61K31/47 ,  A61K31/5377 ,  A61K31/7036 ,  A61K45/06 ,  A61P11/06 ,  A61P11/08 ,  A61K31/191

Abstract: The present disclosure features disclosed method of treating disorders such as COPD, bronchitis and/or asthma using disclosed compounds, optionally together with one or more additional active agents. Contemplated methods include administrating orally or by inhalation to a patient one or more disclosed compounds.

公开(公告)号：US20180105517A1

公开(公告)日：2018-04-19

申请号：US15562814

申请日：2016-03-30

Applicant: Hovione Scientia Limited

Inventor： Zita MENDES ,  Constança CACELA ,  Ana Carina CONSTANTINO ,  Bruno SANTOS

IPC: C07D453/02 ,  B01D9/00 ,  A61K31/439 ,  A61K47/26 ,  A61K9/00 ,  A61P11/08

CPC classification number: C07D453/02 ,  A61K9/0075 ,  A61K31/439 ,  A61K47/26 ,  A61P11/08 ,  B01D9/0027 ,  B01D9/005 ,  C07B2200/13

Abstract: A process for preparing (3R)-3-[2-Hydroxy(di-2-thienyl)acetoxy]-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide (aclidinium bromide) comprises reacting 2-hydroxy-2,2-dithien-2-ylacetic acid 1-azabicyclo[2.2.2]oct-3(R)yl methyl ester and 3-phenoxypropyl bromide, wherein the reaction takes place in a solvent or mixture of solvents selected from the group of amides and/or the group of solvents with a sulfoxide group. Also provided is a crystalline aclidinium bromide characterized by a powder XRPD pattern having peaks at 7.7±0.2° 2θ, 10.4±0.2° 2θ, 13.2±0.2° 2θ, 13.8±0.2° 2θ, 19.9±0.2° 2θ, 20.3±0.2° 2θ, 20.8±0.2° 2θ, 24.2±0.2° 2θ, 25.7±0.2° 2θ, 26.1±0.2° 2θ, 29.2±0.2° 2θ, 30.8±0.2° 2θ. A pharmaceutical composition comprises aclidinium bromide according to the invention and a pharmaceutically acceptable excipient.

公开(公告)号：US20070104655A1

公开(公告)日：2007-05-10

申请号：US11448765

申请日：2006-06-08

Applicant: Bernd Zierenberg ,  Holger Memmesheimer ,  Christine Lunkenheimer ,  Sven Calander ,  Alf Niemi ,  Thomas Nilsson ,  Mattias Myrman

Inventor： Bernd Zierenberg ,  Holger Memmesheimer ,  Christine Lunkenheimer ,  Sven Calander ,  Alf Niemi ,  Thomas Nilsson ,  Mattias Myrman

IPC: A61K31/4745 ,  A61K9/14 ,  A61M11/00

CPC classification number: A61K9/0075 ,  A61K9/008 ,  A61K31/439 ,  A61P11/06 ,  A61P11/08

Abstract: A medical product suitable for storing and delivering a pre-metered dose of tiotropium, devices containing the same, and methods of using the same.

Abstract translation: 适用于储存和递送预定剂量的噻托溴铵的医药产品，含有它们的装置及其使用方法。

公开(公告)号：US20240165054A1

公开(公告)日：2024-05-23

申请号：US18424452

申请日：2024-01-26

Applicant: Verona Pharma PLC

Inventor： Tara Renae RHEAULT ,  Kathleen RICKARD ,  Thomas BENGTSSON

IPC: A61K31/137 ,  A61K9/00 ,  A61K31/519 ,  A61K47/02 ,  A61K47/26 ,  A61P11/08

CPC classification number: A61K31/137 ,  A61K9/0078 ,  A61K31/519 ,  A61K47/02 ,  A61K47/26 ,  A61P11/08

Abstract: The present invention relates to a compound for use in a method for decreasing the frequency and/or severity of chronic obstructive pulmonary disease (COPD) exacerbations in a patient suffering from COPD, wherein the compound is ensifentrine or a pharmaceutically acceptable salt thereof. The present invention also relates to a compound for use in a method for treating chronic obstructive pulmonary disease (COPD) in a patient, wherein: the compound is ensifentrine or a pharmaceutically acceptable salt thereof; and the patient is susceptible to COPD exacerbations.

公开(公告)号：US20240165023A1

公开(公告)日：2024-05-23

申请号：US18417410

申请日：2024-01-19

Applicant: Verona Pharma PLC

Inventor： Peter Lionel Spargo ,  Tara Renae Rheault ,  Doris K. Weilert

IPC: A61K9/00 ,  A61K9/08 ,  A61K31/519 ,  A61K47/02 ,  A61K47/26 ,  A61P11/08

CPC classification number: A61K9/0078 ,  A61K9/08 ,  A61K31/519 ,  A61K47/02 ,  A61K47/26 ,  A61P11/08

Abstract: The invention relates to a liquid pharmaceutical composition comprising a dose of a compound which is ensifentrine or a pharmaceutically acceptable salt thereof, wherein the liquid pharmaceutical composition provides a blood plasma concentration of ensifentrine after administration by inhalation to a human subject having COPD, which blood plasma concentration of ensifentrine has: a mean Cmax of from about 400 pg/mL to about 720 pg/mL; and/or a mean AUC0-tau of from about 2000 pg/mL*h to about 3000 pg/mL*h; and/or a mean Tmax at from about 0.6 hours to about 1.5 hours. The invention also provides a method of treating COPD.

公开(公告)号：US11718853B2

公开(公告)日：2023-08-08

申请号：US17366835

申请日：2021-07-02

Applicant: Onspira Therapeutics, Inc.

Inventor： Roy C Levitt, Jr.

IPC: A61K9/00 ,  C12N15/113 ,  A61K38/20 ,  A61K31/70 ,  C07K14/715 ,  A61P11/08 ,  A61K31/7088 ,  A61K31/713 ,  A61K38/17 ,  A61K39/395 ,  A61K45/06

CPC classification number: C12N15/1136 ,  A61K9/007 ,  A61K9/008 ,  A61K9/0075 ,  A61K9/0078 ,  A61K31/70 ,  A61K31/7088 ,  A61K31/713 ,  A61K38/1793 ,  A61K38/20 ,  A61K38/2006 ,  A61K39/3955 ,  A61K45/06 ,  A61P11/08 ,  C07K14/7155 ,  C12N15/113 ,  C07K2319/30 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2320/30

Abstract: The present invention is drawn to methods and compositions for treating inflammatory disorders of the lower airways, comprising administering an effective amount of an agent, which modulates the expression and/or activity of a proinflammatory cytokine or fragment thereof, preferably in a human. The proinflammatory cytokine contemplated by the invention includes IL-1, IL-6, IL-8 and TNF-alpha. The present invention describes a kit comprising a delivery device and a pharmaceutical composition for administration of the agent. The pharmaceutical composition includes at least one proinflammatory cytokine inhibitor, optionally one or more additional active ingredients, and at least one pharmaceutically active carrier. The delivery device further comprises a nebulizer, an inhaler, a powder dispenser, an intrapulmonary aerosolizer and a sub-miniature aerosolizer.

公开(公告)号：US20180333382A1

公开(公告)日：2018-11-22

申请号：US15982599

申请日：2018-05-17

Applicant: DS Biopharma Limited

Inventor： John Climax ,  Mehar Manku ,  David Coughlan

IPC: A61K31/202 ,  A61K9/00 ,  A61K9/48 ,  A61P11/02 ,  A61P11/06 ,  A61P11/08 ,  A61P17/04

CPC classification number: A61K31/202 ,  A61K9/0053 ,  A61K9/48 ,  A61P11/02 ,  A61P11/06 ,  A61P11/08 ,  A61P17/04

Abstract: The present disclosure provides orally deliverable pharmaceutical compositions comprising DGLA and methods of using same to treat a variety of conditions and disorders.

公开(公告)号：US20180325815A1

公开(公告)日：2018-11-15

申请号：US15975017

申请日：2018-05-09

Applicant: CHIESI FARMACEUTICI S.p.A.

Inventor： Alessandro CAVECCHI ,  Cristiana MERUSI ,  Fausto PIVETTI ,  Francesca SCHIARETTI

IPC: A61K9/00 ,  A61K31/40 ,  A61K9/14 ,  A61K47/12 ,  A61K47/26 ,  A61P11/06 ,  A61P11/08

CPC classification number: A61K9/0075 ,  A61K9/145 ,  A61K31/167 ,  A61K31/40 ,  A61K31/573 ,  A61K45/06 ,  A61K47/12 ,  A61K47/26 ,  A61K2300/00 ,  A61P11/06 ,  A61P11/08

Abstract: A process for preparing a dry powder formulation for inhalation comprising a combination of an anti-cholinergic, a long-acting beta2-adrenoceptor agonist, and, optionally, an inhaled corticosteroid, is provided.

公开(公告)号：US20240116874A1

公开(公告)日：2024-04-11

申请号：US18506737

申请日：2023-11-10

Applicant: Bayer Aktiengesellschaft ,  Bayer Pharma Aktiengesellschaft

Inventor： Britta OLENIK ,  Birgit KEIL ,  Bernd RÖSLER ,  Peter FEY ,  Heiko SCHIRMER ,  Guido BECKER ,  Julian EGGER ,  Clemens BOTHE ,  Helene FABER

IPC: C07D215/48 ,  A61K9/00 ,  A61P9/12 ,  A61P11/08

CPC classification number: C07D215/48 ,  A61K9/0075 ,  A61P9/12 ,  A61P11/08

Abstract: The present invention relates to a novel and improved process for preparing (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4′-(trifluo-romethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid of the formula (I) and to novel crystalline forms of it, which is i.a. the pseudopolymorphic form monohydrate I (I-M-I) or the pseudopolymorphic form monohydrate II (I-M-II), furthermore the present invention relates to a novel and selective crystallization process for preparation of the pseudopolymorphic form monohydrate I (I-M-I) or the pseudopolymorphic form monohydrate II (I-M-II), preferably monohydrate I of formula (I-M-I) and to pharmaceutical compositions comprising monohydrate I of formula (I-M-I) and to its use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of pulmonary and cardiopulmonary and cardiovascular diseases.

公开(公告)号：US11680054B2

公开(公告)日：2023-06-20

申请号：US17255264

申请日：2019-07-05

Applicant: Arcede Pharma AB

Inventor： Maria Dalence ,  Martin Johansson ,  Viveca Thornqvist Oltner ,  Jörgen Toftered ,  David Wensbo

IPC: C07D401/12 ,  A61P11/08 ,  A61K31/4725 ,  A61K45/06 ,  C07D401/14

CPC classification number: C07D401/12 ,  A61K31/4725 ,  A61K45/06 ,  A61P11/08 ,  C07D401/14

Abstract: The invention relates to novel molecules having the general formula (I), and which molecules are useful to treat a disorder or disease characterized by bronchoconstriction, e.g. COPD and asthma inflammation and/or vasoconstriction, e.g. hypertension.